1 / 14

Type 1 Diabetes Treatment Options

Type 1 Diabetes Treatment Options. Part 1. Stanley Schwartz Mark Stolar Emeritus, Univ of Pa. Type 1 Diabetes. Diabetes mellitus type 1 (IDDM)

shirleysmith
Télécharger la présentation

Type 1 Diabetes Treatment Options

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Type 1 Diabetes Treatment Options Part 1 Stanley Schwartz Mark Stolar Emeritus, Univ of Pa

  2. Type 1 Diabetes • Diabetes mellitus type 1 (IDDM) Hyperglycemia resulting from the autoimmune destruction of the insulin-producing beta cells in the pancreas- insulin therapy is essential for survival= insulin dependent unlike type 2 diabetes where insulin use defines insulin treated not dependent

  3. Pathogenesis of Type 1 Diabetes Environmentaltriggers andregulators Immunedysregulation Loss of first-phase insulin response Interactions betweengenes impartingsusceptibility and resistance May be relapsing/remitting Glucose intolerance β-cell Mass Variable insulitisβ-cell sensitivity to injury Overt diabetes Pre-diabetes Time Adapted with permission from Atkinson MA, Eisenbarth GS. Lancet. 2001;358:221

  4. Type 1 Diabetes • Insulin-deficient state • Therapeutic goal: replace insulin • Strategy: provide replacement insulin in manner that mimics normal fasting/prandial physiology • This cannot always be done with current insulin analogues • Goal to reduce microvascular complications. Is postprandial hyperglycemia more pathogenic?

  5. 76% 59% 39% 54% 64% DCCTMicrovascular Complication Event Rates and Risk Reductions Cumulative Incidence (%) 1 2 3 2 1 1. DCCT Research Group. Ophthalmology. 1995;102:647 2. DCCT Research Group. Kidney Int. 1995;47:1703 3. DCCT Research Group. AnnIntern Med. 1995;122:561

  6. :1. Hypoglycemia2. Weight gain3. Glycemic, including daytime, variability4. Doesn’t address non-insulin mediated causes of hyperglycemia in type 1 diabetes The Downside to Intensive Insulin Management

  7. DCCT RESULTS Severe Hypoglycemia 100 • Persistent three-fold increase in INT • Increased risk of multiple episodes within same patient (INT = 22%, CON = 4%) • Number of prior episodes was strongest predictor of future risk • Current A1C not solely predictive of risk 80 60 Intensive Rate/100 Patient Years 40 20 Conventional 0 5 6 7 8 9 10 11 12 13 14 HbA1c (%) During Study DCCT Research Group, Diabetes 1997;46:271-286

  8. Hypoglycemia Unawareness Is a Dangerous Complication of T1DM • Each episode of hypoglycemia reduces counterregulatory response to low glucose even after one episode • Reduction in catecholamine response decreases awareness/symptoms even after a single episode • Nocturnal hypoglycemia is most pathogenic and unrecognized. Hypoglycemic awareness decreases significantly in the elderly

  9. CV Consequences of Hypoglycemia • Prolonged QT- intervals- Diabetologia 52:42,2009 • Can be of pronged duration IJCP Sup 129, 7/02 • Greater with higher catecholamine levels Europace 10,860 • Associated with Angina Diabetes Care 26, 1485, 2003 / Ischemic EKG changes Porcellati, ADA2010 • Associated with Arrhythmias • Associated with Sudden Death Endocrine Practice 16,¾ 2010 • Increased Glycemic Variabilty- Adverse ICU outcomes/Increased vascular inflammation Hirsch ADA2010

  10. :1. Hypoglycemia2. Weight gain3.Glycemic, including daytime, variability4. Doesn’t address non-insulin mediated causes of hyperglycemia in type 1 diabetes The Downside to Intensive Insulin Management

  11. 30 10.0 25 7.5 20 15 Δ Weight (kg) 5.0 Δ Weight (kg) 10 5 2.5 0 0 -5 1 2 3 4 0 3 6 9 12 15 Quartile of Weight Gain Time (y) Consequences of Intensive Insulin Therapy Weight Gain UKPDS (Type 2) DCCT (Type 1) Intensive Conventional Data from Purnell J, et al. JAMA 1998; 280:140-146 Data from UKPDS Group (UKPDS 33). Lancet 1998; 352:837-853

  12. +8.7 kg +4.6 kg -2.2% -2.6% Yki-Jarvinen 1999 Henry 1993 Weight Gain MEALTIME INSULIN THERAPY 10 8 6 Δ Weight (kg) 4 2 0 BID Insulin Intensive BID Insulin 12 11 10 9 8 A1C (%) ADA Goal 7 6 5 4

  13. :1. Hypoglycemia2. Weight gain3. Glycemic, including daytime, variability4. Doesn’t address non-insulin mediated causes of hyperglycemia in type 1 diabetes The Downside to Intensive Insulin Management

More Related